While many believe the agents to be potential game changers, evidence is still lacking in psoriatic disease, and experts urge ...

Individuals with type 2 diabetes who receive treatment with GLP-1 RAs do not have an increased risk for acute pancreatitis.

Landmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

Patients with idiopathic intracranial hypertension who use a GLP-1 receptor agonist are less likely to experience symptoms, require medications, or undergo surgery.

For older adults with diabetes, there is no clear evidence to suggest that the incidence of dementia differs for those using ...

For patients with idiopathic intracranial hypertension (IIH), glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment ...

For patients with type 2 diabetes, GLP-1 RAs are associated with an increased risk for GERD and its complications compared with SGLT-2 inhibitors.

GLP-1 receptor agonists such as semaglutide and liraglutide promote significant weight loss and improved glycemic control, ...

For older adults with diabetes, there is no clear evidence to suggest that the incidence of dementia differs for those using glucagon-like peptide 1 receptor agonists (GLP-1 RAs) versus dipeptidyl ...

GLP-1 drugs, which have seen widespread success, have been linked to a number of cases of pancreatitis in the UK, which have led to hospitalisations and even deaths.